ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,908Medicare Part D Prescriptions Filled, Including Refills

Rank: 13 out of 212

$527K Total Retail Price of All Prescriptions

Rank: 17 out of 212

345 Patients Receiving at Least One Drug in Part D
82%Patients 65 Years and Older
48% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Hawaii
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 345 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

15% of this provider’s 345 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

1% of this provider’s 7,571 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Hawaii
LEVOTHYROXINE SODIUM 377 336 1 7
LISINOPRIL 333 272 2 2
ATORVASTATIN CALCIUM 240 223 3 6
FUROSEMIDE 220 191 4 11
AMLODIPINE BESYLATE 214 180 5 3
LOSARTAN POTASSIUM 208 171 6 4
METOPROLOL SUCCINATE 206 184 7 14
HYDROCHLOROTHIAZIDE 203 171 8 8
HYDROCODONE-ACETAMINOPHEN 173 151 S3 9 10
SIMVASTATIN 168 134 10 1
MIRTAZAPINE 161 160 11 43
METFORMIN HCL 143 62 12 5
LOVASTATIN 141 95 13 12
OMEPRAZOLE 128 107 14 9
NAMENDA 127 126 15 28
ATENOLOL 126 87 16 13
POTASSIUM CHLORIDE 121 102 17 27
SERTRALINE HCL 104 89 18 47
RANITIDINE HCL 99 79 19 29
WARFARIN SODIUM 92 92 20 19
GABAPENTIN 90 86 21 22
METOPROLOL TARTRATE 90 82 21 17
TAMSULOSIN HCL 89 79 23 21
ALLOPURINOL 88 43 24 18
DONEPEZIL HCL 87 87 25 25
CYMBALTA 83 83 26 71
CITALOPRAM HBR 79 69 27 56
ESCITALOPRAM OXALATE 79 79 27 98
POLYETHYLENE GLYCOL 3350 77 64 29 91
PANTOPRAZOLE SODIUM 75 73 30 44
CLOPIDOGREL 75 75 30 31
TRIAMCINOLONE ACETONIDE 74 64 32 95
CARVEDILOL 71 59 33 23
LISINOPRIL-HYDROCHLOROTHIAZIDE 68 51 34 24
METFORMIN HCL ER 68 59 34 34
ALENDRONATE SODIUM 67 67 36 16
GLIMEPIRIDE 61 58 37 61
FELODIPINE ER 59 48 38 36
NEXIUM 58 51 39 65
DIGOXIN 56 56 40 41
SULFAMETHOXAZOLE-TRIMETHOPRIM 52 44 41 110
ADVAIR DISKUS 52 36 41 33
QUETIAPINE FUMARATE 51 46 43 146
PLAVIX 50 50 44 54
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.